The Journal of Therapeutic Ultrasound Publishes Article on SonaCare Medical's Sonablate® HIFU Technology

CHARLOTTE, N.C., Sept. 26, 2017 /PRNewswire/ -- SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, reports on a new publication in the Journal of Therapeutic Ultrasound. The article is titled, "Clinical validation of real-time tissue change monitoring during prostate tissue ablation with high intensity focused ultrasound."

TCM, a utility found only in Sonablate®, analyzes automatically components of the ultrasound imaging signal after each small zone of ablation is delivered to assist in deciding whether sufficient energy was absorbed by the treated tissue.  This allows Sonablate® physicians to decide whether it is necessary to go back and add additional energy to any specific portion of the total region of ablation. 

According to Dr. Mark Carol, CEO of SonaCare Medical, "The publishing of this work provides validation for a tool that SonaCare believes to be an important differentiator for SonaCare technology.  The feedback it provides allows physicians to use unique Sonablate treatment delivery controls to adjust the treatment in response to how any given volume of tissue responds to energy delivery, leading to better clinical outcomes in terms of efficacy and safety.  Dr. Sanghvi, the inventor of the Sonablate technology and one of the founders of our company, has worked tirelessly for decades to bring the benefits of HIFU to the clinical arena.  We are delighted to see this aspect of his team's seminal work in print."

Since Sonablate® received FDA clearance on October 09, 2015, more than 1,200 patients have had a Sonablate HIFU prostate procedure across the 40+ locations in the U.S., including placements at top-tier academic institutions in California, Indiana, Oklahoma, Maryland, New York, Arizona, and Texas. 

About SonaCare Medical, LLC

SonaCare Medical is a world leader in minimally invasive focused ultrasound technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S.; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 50 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

Forward Looking Statements. 
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

SOURCE SonaCare Medical, LLC